Precision BioSciences Net Income
| DTIL Stock | USD 3.81 0.01 0.26% |
As of the 10th of February, Precision BioSciences holds the Coefficient Of Variation of (486.57), variance of 14.31, and Risk Adjusted Performance of (0.16). Precision BioSciences technical analysis gives you tools to exploit past prices in attempt to determine a pattern that determines the direction of the company's future prices. Please check Precision BioSciences market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Precision BioSciences is priced some-what accurately, providing market reflects its current price of 3.81 per share. Given that Precision BioSciences has information ratio of (0.23), we recommend you to check out Precision BioSciences's recent market performance to make sure the company can sustain itself at a future point.
Precision BioSciences Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 108.6691 | Revenue | Earnings Share (8.96) |
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 6.5 M | 6.8 M | |
| Net Loss | -100.5 M | -95.4 M | |
| Net Income | 6.5 M | 6.8 M | |
| Net Income Per Share | 0.94 | 0.99 | |
| Net Income Per E B T | 1.30 | 1.06 |
Precision | Net Income | Build AI portfolio with Precision Stock |
Historical Net Income data for Precision BioSciences serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Precision BioSciences represents a compelling investment opportunity.
Latest Precision BioSciences' Net Income Growth Pattern
Below is the plot of the Net Income of Precision BioSciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Precision BioSciences financial statement analysis. It represents the amount of money remaining after all of Precision BioSciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Precision BioSciences' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Precision BioSciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 7.17 M | 10 Years Trend |
|
Net Income |
| Timeline |
Precision Net Income Regression Statistics
| Arithmetic Mean | (29,996,876) | |
| Geometric Mean | 17,723,100 | |
| Coefficient Of Variation | (133.22) | |
| Mean Deviation | 31,940,794 | |
| Median | (8,251,000) | |
| Standard Deviation | 39,961,739 | |
| Sample Variance | 1596.9T | |
| Range | 118.8M | |
| R-Value | (0.22) | |
| Mean Square Error | 1622.5T | |
| R-Squared | 0.05 | |
| Significance | 0.40 | |
| Slope | (1,724,545) | |
| Total Sum of Squares | 25551T |
Precision Net Income History
Other Fundumenentals of Precision BioSciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Precision BioSciences Net Income component correlations
Precision Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Precision BioSciences is extremely important. It helps to project a fair market value of Precision Stock properly, considering its historical fundamentals such as Net Income. Since Precision BioSciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Precision BioSciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Precision BioSciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. Projected growth potential of Precision fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Precision BioSciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (8.96) | Revenue Per Share | Quarterly Revenue Growth (0.98) | Return On Assets | Return On Equity |
Precision BioSciences's market price often diverges from its book value, the accounting figure shown on Precision's balance sheet. Smart investors calculate Precision BioSciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Precision BioSciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Precision BioSciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Precision BioSciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Precision BioSciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Precision BioSciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Precision BioSciences.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Precision BioSciences on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Precision BioSciences or generate 0.0% return on investment in Precision BioSciences over 90 days. Precision BioSciences is related to or competes with Metagenomi Common, Alx Oncology, Artiva Biotherapeutics, Sutro Biopharma, Fractyl Health, ATyr Pharma, and Connect Biopharma. Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic... More
Precision BioSciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Precision BioSciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Precision BioSciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.23) | |||
| Maximum Drawdown | 15.28 | |||
| Value At Risk | (7.57) | |||
| Potential Upside | 5.64 |
Precision BioSciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Precision BioSciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Precision BioSciences' standard deviation. In reality, there are many statistical measures that can use Precision BioSciences historical prices to predict the future Precision BioSciences' volatility.| Risk Adjusted Performance | (0.16) | |||
| Jensen Alpha | (0.86) | |||
| Total Risk Alpha | (1.20) | |||
| Treynor Ratio | (0.91) |
Precision BioSciences February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.16) | |||
| Market Risk Adjusted Performance | (0.90) | |||
| Mean Deviation | 2.89 | |||
| Coefficient Of Variation | (486.57) | |||
| Standard Deviation | 3.78 | |||
| Variance | 14.31 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (0.86) | |||
| Total Risk Alpha | (1.20) | |||
| Treynor Ratio | (0.91) | |||
| Maximum Drawdown | 15.28 | |||
| Value At Risk | (7.57) | |||
| Potential Upside | 5.64 | |||
| Skewness | (0.45) | |||
| Kurtosis | 0.5557 |
Precision BioSciences Backtested Returns
Precision BioSciences maintains Sharpe Ratio (i.e., Efficiency) of -0.17, which implies the firm had a -0.17 % return per unit of risk over the last 3 months. Precision BioSciences exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Precision BioSciences' Variance of 14.31, risk adjusted performance of (0.16), and Coefficient Of Variation of (486.57) to confirm the risk estimate we provide. The company holds a Beta of 0.87, which implies possible diversification benefits within a given portfolio. Precision BioSciences returns are very sensitive to returns on the market. As the market goes up or down, Precision BioSciences is expected to follow. At this point, Precision BioSciences has a negative expected return of -0.68%. Please make sure to check Precision BioSciences' jensen alpha, as well as the relationship between the skewness and day median price , to decide if Precision BioSciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.69 |
Good predictability
Precision BioSciences has good predictability. Overlapping area represents the amount of predictability between Precision BioSciences time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Precision BioSciences price movement. The serial correlation of 0.69 indicates that around 69.0% of current Precision BioSciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.69 | |
| Spearman Rank Test | 0.61 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Precision Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Precision BioSciences reported net income of 7.17 M. This is 97.9% lower than that of the Biotechnology sector and 89.77% lower than that of the Health Care industry. The net income for all United States stocks is 98.74% higher than that of the company.
Precision Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Precision BioSciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Precision BioSciences could also be used in its relative valuation, which is a method of valuing Precision BioSciences by comparing valuation metrics of similar companies.Precision BioSciences is currently under evaluation in net income category among its peers.
Precision BioSciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Precision BioSciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Precision BioSciences' managers, analysts, and investors.Environmental | Governance | Social |
Precision BioSciences Institutional Holders
Institutional Holdings refers to the ownership stake in Precision BioSciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Precision BioSciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Precision BioSciences' value.| Shares | Blackrock Inc | 2025-06-30 | 57.5 K | Dimensional Fund Advisors, Inc. | 2025-06-30 | 53.6 K | Commonwealth Equity Services Inc | 2025-06-30 | 53.4 K | Ubs Group Ag | 2025-06-30 | 51.6 K | Royal Bank Of Canada | 2025-06-30 | 42 K | Northern Trust Corp | 2025-06-30 | 40.3 K | State Street Corp | 2025-06-30 | 26.2 K | Two Sigma Investments Llc | 2025-06-30 | 16.4 K | Lpl Financial Corp | 2025-06-30 | 13.4 K | Bleichroeder Lp | 2025-06-30 | 1.1 M | Aquilo Capital Management, Llc | 2025-03-31 | 726.1 K |
Precision Fundamentals
| Return On Equity | -2.05 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 75.85 M | ||||
| Shares Outstanding | 24.07 M | ||||
| Shares Owned By Insiders | 5.86 % | ||||
| Shares Owned By Institutions | 44.35 % | ||||
| Number Of Shares Shorted | 1.32 M | ||||
| Price To Earning | (6.10) X | ||||
| Price To Book | 5.51 X | ||||
| Price To Sales | 131.05 X | ||||
| Revenue | 68.7 M | ||||
| Gross Profit | 698 K | ||||
| EBITDA | 13.53 M | ||||
| Net Income | 7.17 M | ||||
| Cash And Equivalents | 184.14 M | ||||
| Cash Per Share | 1.66 X | ||||
| Total Debt | 30.05 M | ||||
| Debt To Equity | 0.27 % | ||||
| Current Ratio | 4.59 X | ||||
| Book Value Per Share | 1.38 X | ||||
| Cash Flow From Operations | (58.45 M) | ||||
| Short Ratio | 5.07 X | ||||
| Earnings Per Share | (8.96) X | ||||
| Target Price | 32.5 | ||||
| Number Of Employees | 67 | ||||
| Beta | 1.31 | ||||
| Market Capitalization | 91.47 M | ||||
| Total Asset | 136.39 M | ||||
| Retained Earnings | (482.46 M) | ||||
| Working Capital | 80.01 M | ||||
| Current Asset | 174.05 M | ||||
| Current Liabilities | 23.86 M | ||||
| Net Asset | 136.39 M |
About Precision BioSciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Precision BioSciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Precision BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Precision BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. Projected growth potential of Precision fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Precision BioSciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (8.96) | Revenue Per Share | Quarterly Revenue Growth (0.98) | Return On Assets | Return On Equity |
Precision BioSciences's market price often diverges from its book value, the accounting figure shown on Precision's balance sheet. Smart investors calculate Precision BioSciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Precision BioSciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Precision BioSciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Precision BioSciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.